Global, regional, and national prevalence of second-hand smoke and attributable disease burden in 204 countries and territories, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 - The Lancet

Pilots and air traffic controllers in the US could soon have an easier time achieving a healthy mental altitude – a move with implications for the safety of air travel in America. The US Senate recently approved bills aimed at encouraging aviation professionals struggling with a mental health condition to get treatment. The House and president must still approve the legislation, but if that happens, the law could help those with depression and anxiety who are reluctant to seek medical care because they worry it will hurt their high-pressure career. “It starts breaking down the stigma and showing that when you raise your hand asking for help, it is no longer a third rail,” said Chris Finlayson, a pilot and executive director of the Pilot Mental Health Campaign. A 2016 survey of more than 1,800 pilots found that almost 13% met the criteria for a depression diagnosis and 4% reported having suicidal thoughts, according to a study published in the journal Environmental Health. Among European airline pilots, a quarter suffered from anxiety and 40% displayed alcohol misuse, according to a 2025 report in the Frontiers in Public Health journal.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.